aTyr Pharma to Present at September Investor Conferences
aTyr Pharma (Nasdaq: LIFE) announced its participation in two key investor conferences in September 2020. Sanjay S. Shukla, M.D., President and CEO, will provide updates at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15 at 10:30 a.m. ET and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22 at 10:50 a.m. ET. Both events will be held virtually, and presentations will be available for replay on the company's website for 90 days post-event.
- None.
- None.
SAN DIEGO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company will present at two investor conferences in September.
Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a company update at the H.C. Wainwright 22nd Annual Global Investment Conference, which is being held September 14-16, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, which is being held September 21-23. Both conferences will take place in a virtual format.
Details of the events are as follows:
Conference: H.C. Wainwright 22nd Annual Global Investment Conference
Date: Tuesday September 15, 2020
Presentation Time: 10:30 a.m. Eastern Time
Conference: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Tuesday September 22, 2020
Presentation Time: 10:50 a.m. Eastern Time
A replay of the live webcast of each presentation will be available on the Investor’s section of the Company’s website at www.atyrpharma.com, and will be available for 90 days following each event.
About aTyr
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.
| Contact: | |
| Ashlee Dunston | |
| Investor Relations, aTyr Pharma | |
| adunston@atyrpharma.com |
FAQ
When will aTyr Pharma present at the H.C. Wainwright conference?
What is the date of the Oppenheimer Fall Healthcare Summit presentation by aTyr Pharma?
Where can I find the replay of aTyr Pharma's conference presentations?
What is the stock symbol for aTyr Pharma?
Who will present at the investor conferences for aTyr Pharma?
